Table 1.
Patient characteristics
| Age | Sex | Comorbidities | Domiciliary O2 | Baseline Sat O2% | Previous COVID treatment |
DC | Death | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCQ∗ | L/R† | TZM‡ | RDM§ | ATB | GC | AT‖ | ||||||||
| 1 | 76 | F | DM | N | 95 | Y | Y | Y | N | Y | Y | Y | - | Y |
| 2 | 86 | M | HBP, parotid cancer | N | - | Y | N | N | N | Y | Y | N | Y | N |
| 3 | 68 | M | DM, HBP, COPD | Y | 95 | Y | N | N | N | Y | Y | N | Y | Y |
| 4 | 90 | M | DM, HBP, ischemic heart disease | N | 90 | Y | N | N | N | Y | Y | Y | Y | N |
| 5 | 53 | M | Obesity, DL | N | 90 | Y | N | Y | Y | Y | Y | Y | Y | N |
| 6 | 58 | F | Obesity, DL | N | 88 | Y | N | N | N | Y | Y | Y | Y | N |
| 7 | 55 | M | DL, ischemic heart disease, chronic hepatitis B, mixed connective tissue disease | N | 86 | Y | Y | N | N | Y | Y | Y | Y | N |
| 8 | 64 | M | HBP, obesity, hepatitis B, OSA | N | 86 | Y | Y | N | N | Y | Y | Y | Y | N |
| 9 | 56 | M | - | N | 96 | Y | Y | Y | N | Y | Y | Y | Y | N |
Abbreviations: AT = antithrombotic; ATB = antibiotic; COPD = chronic obstructive pulmonary disease; DC = discharged; DL = dyslipidemia; DM = diabetes; GC = glucocorticoids; HBP = high blood pressure; HCQ = hydroxychloroquine; L/R = lopinavir/ritonavir; OSA = obstructive sleep apnea; RDM = remdesivir; TZM = tocilizumab.
∗
HCQ was administered at a dose of 400 mg/12 h the first day and then 200 mg/12 h for 5 d.
†
Lopinavir 200 mg/ritonavir 100 mg, 2 tablets/12 h for 7 d.
‡
Tocilizumab 400 mg with a maximum of 3 doses.
§
Remdesivir 100 mg/24 h during 9 d.
‖
Antithrombotic 40 mg/24 h.